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Hypovitaminosis D is associated with
negative outcome in dogs with protein
losing enteropathy: a retrospective study of
43 cases
K. Allenspach1,4* , J. Rizzo1, A. E. Jergens2 and Y. M. Chang3
Abstract
Background: Hypovitaminosis D has previously been shown to be prevalent amongst dogs with protein losing
enteropathy (PLE).
The hypothesis of this study was that Low 25-hydroxyvitamin D (25(OH) D) serum concentrations could be a risk
factor for negative outcome in dogs with PLE.
Forty-three dogs diagnosed with PLE (2005–2014) and which serum Vitamin D serum concentrations were collected
and archived at −80 Degrees C were analyzed.
Post-diagnostic communication with referring veterinarians was made to determine outcome of PLE dogss: Dogs
which died due to PLE within 4 months after diagnosis (negative outcome group, n = 22) and dogs alive or which
died due to another disease at the end point of the study (1 year after diagnosis, good outcome group, n = 21).
Serum samples taken at the time of diagnosis were analysed for ionized calcium (iCa) concentrations and serum
25(OH) D concentration.
Results: Clinical (CCECAI) scores, age at PLE diagnosis, and iCa concentrations were not significantly different
between dog groups. A significantly greater (p < 0.001) number of PLE dogs treated with hydrolyzed or elimination
diet alone showed good outcome as compared to the PLE negative outcome group. Median serum 25(OH) D
concentration was significantly (p = 0.017) lower in dogs with negative outcome versus PLE dogs with good
outcome. Using logistic regression analysis, 25(OH) D serum concentration was shown to be a statistically
significant factor for outcome determination. Cox regression analysis yielded a hazard ratio of 0.974 (95% CI 0.949, 0.
999) per each one nmol/l increase in serum 25(OH) D concentration.
Conclusions: Low serum 25(OH) D concentration in PLE dogs was significantly associated with poor outcome.
Further studies are required to investigate the clinical efficacy of Vitamin D (cholecalciferol) as a potential
therapeutic agent for dogs with PLE.
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Background
Protein-losing enteropathy (PLE) in dogs is a clinical
syndrome characterized by loss of protein through the
intestines [1]. There are three major causes for PLE in
dogs including inflammatory bowel disease (IBD), primary
intestinal lymphangiectasia (IL), and intestinal lymphoma
[1]. Apart from dogs diagnosed with intestinal lymphoma,
which generally show poor response to chemotherapy and
short survival times, dogs with PLE secondary to IBD or
primary IL have a variable prognosis [1–5]. Only few
reports describe prospective treatment trials of dogs with
PLE since mortality is high despite intense immunosup-
pressive and nutritional treatment protocols [2, 3].
Possible life-threatening complications include intractable
diarrhea, extreme malnutrition, and thromboembolic
disease [6]. Risk factors associated with poor outcome
have not been well characterized in PLE dogs to date.
Several breeds are predisposed to the development of
PLE, with Yorkshire Terriers having better outcome in
some instances [4] while disease in Rottweilers generally
carries a poor prognosis [1]. In addition, there is evidence
that biomarkers, such as serum C-reactive protein, serum
canine pancreatic lipase immunoreactivity, and fecal
alpha-1 proteinase inhibitor concentrations, are more
commonly elevated in those dogs having the shortest
survival times [7, 8]. Electrolyte disturbances, such as low
total and ionized calcium concentrations and hypo-
magnesemia, have also been reported in some PLE in dogs
[9, 10]. It is hypothesised that the ionized hypocalcemia in
IBD cases could be caused by reduced Vit D or calcium–
absorption, reduced dietary intake, and/or Vitamin D re-
ceptor polymorphisms in impaired Vitamin D metabolism
[11]. Furthermore, low serum concentrations of 25(OH) D
have recently been described in dogs with chronic enter-
opathies [12], and have been shown to be associated with
negative outcome [13]. We therefore sought to investigate
the presence of low iCa and 25(OH) D serum concentra-
tions in dogs with PLE and whether these variables were
associated with negative outcome.
Methods
Aim, design and setting of the study
The aim of the current study was to assess the prevalence of
decreased 25(OH) D serum concentrations in dogs with
PLE caused by IBD. In addition, we investigated whether
25(OH) D could serve as a prognostic indicator of outcome.
This was a retrospective study including 43 cases seen
at the Royal Veterinary College, University of London,
over the time period of 2005–2014.
Animals
The medical records of dogs referred to the Queen Mother
Hospital for Animals (QMHA), Royal Veterinary College
between 2005 and 2014 were reviewed retrospectively to
identify dogs with a clinical diagnosis of PLE. The diagnosis
of PLE was made if all of the following applied: (1) history
of chronic gastrointestinal disease (including weight loss,
vomiting, diarrhea, decreased appetite); (2) panhypoprotei-
nemia (serum albumin less than 2.8 g/dL and serum globu-
lin less than 2.1 g/dL; reference ranges 2.8–3.9 and 2.1–
4.1 g/dL, respectively); (3) diagnostic tests including per-
formance of complete blood count, biochemistry profile,
urinalysis, abdominal ultrasound, ACTH stimulation test,
serum trypsin like immunoreactivity (TLI), and canine
pancreatic lipase immunoreactivity (cPLI) serum assays to
reflect the presence or absence of primary GI disease versus
extra-intestinal disease, (4) histopathological confirmation
of IL or IBD with secondary IL; (5) exclusion of hepatic
dysfunction by serum bile acid stimulation test; and (5) ab-
sence of proteinuria. Proteinuria was excluded in all dogs
on the basis of a negative urine dipstick or a urine protein:
creatinine ratio of <0.5. In addition, at the time of PLE
diagnosis, all dogs had to have a clinical disease activity
index (Canine Chronic Enteropathy Clinical Activity Index,
CCECAI [14]) recorded by the clinician, and a serum
sample frozen within 30 min after collection and stored at
−80 Degrees Celsius until later analysis.
Clinical data
Follow up communication with referring veterinarians
was made to determine post-diagnostic outcome of PLE
dogs. In accordance with previoulsy published studies,
dogs were divided into two groups: The first group con-
sisted of dogs which had died from their illness or were
euthanized due to intractable clinical disease within
4 months after diagnosis [4] (negative outcome group),
and the second group consisted of PLE dogs that were
alive or had died due to non-PLE disease at least 1 year
after diagnosis (good outcome group). Individual treat-
ments of dogs were also categorized into two groups:
Group 1 dogs comprised those who received either an
elimination diet (single protein diet that the dog had not
been given before, using a commercially available veterin-
ary therapeutic diet) or a hydrolyzed diet (commercially
available, hydrolyzed ingredient veterinary therapeutic
diet) on an exclusive basis (diet group); Group 2 dogs
consisted of dogs who were prescribed elimination or
hydrolyzed diet in conjunction with immunosuppressive
drugs, including combination therapy with prednisolone,
cyclosporine, and/or azathioprine.
Measurement of ionized calcium (iCa) and serum 25(OH)
D concentrations
Vitamin D status was assessed by the measurement of
serum concentrations of 25-hydroxyvitamin D (25[OH] D),
which is the most widely used approach to analyze whole
body vitamin D status [15]. At the time of diagnosis, dogs
had samples collected for biochemical and hematological
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analysis. Residual serum samples were then frozen at −80 °
C within 30 min after collection, until future analysis.
Ionized calcium concentrations were measured using an
ion specific electrode and 25(OH) D was measured using
commercially available radioimmunoassays (RIA) that have
been validated for use in veterinary medicine [16]. Samples
were shipped on dry ice to the Michigan State University’s
Diagnostic Center for Population and Animal Health,
(DACPAH)1 for batch analysis. Serum 25(OH) D and iCa
concentrations have previously been shown to be stable
under these conditions [17], and DACPAH1, personal
communication).
Statistical analysis
Differences between dog groups were assessed using a
Mann-Whitney U-test for numerical data or Fisher’s exact
test for categorical data, respectively. Correlations were
analysed using Spearman Rank correlation tests. Breed,
age, serum albumin concentrations, CCECAI scores, treat-
ment group, iCa concentrations and 25(OH) D concentra-
tions were entered into a univariate logistic regression
analysis. Factors that were significantly associated with
outcome in the univariate logistic regression analysis were
then assessed in a multivariable logistic regression.
Kaplan-Meier curve and Cox regression analyses were
used to illustrate and estimate the effect of 25(OH) D
serum concentration on survival times after diagnosis.
Hazard ratio (HR) and 95% confidence interval (CI) were
reported. Statistical analyses were performed with SPSS
version 22 and GraphPad Prism 7 statistical software, with
a p < 0.05 considered statistically significant.
Results
Forty-three PLE dogs were included in the study with 21
dogs having good outcome and 22 dogs having negative
outcome. In the negative outcome group, median sur-
vival time was 19 days (range 1–301 days). In the good
outcome group, 13/22 dogs were still alive at 4 months,
while 9 dogs had been euthanized due to non-PLE re-
lated illnesss. Median survival time in this latter group
was 1095 days (range 515–3130 days).
In the good outcome group, median age was 5.2 years
(range 1–11 years), with six neutered males, three entire
males, nine neutered females, and three entire females
making up this group. Breeds in this cohort included 5
crossbreed dogs, 2 each of Miniature Schnauzers, Labra-
dor Retrievers and Border Collies, and one each of Ameri-
can Bulldog, Weimaraner, Cavalier King Charles Spaniel,
Cocker Spaniel, Griffon, Boxer, English Springer Spaniel,
Jack Russel Terrier, Tibetan Terrier and Standard Poodle.
Histopathological diagnoses in this group were IBD in 16
dogs, and IBD with IL in five dogs. Median age in the
negative outcome group was 6.7 years (range 0.9–
13.7 years), with four neutered males, four entire males,
twelve neutered females, and two entire females in this
group. Breeds included in the negative outcome cohort
included three dogs each of Cavalier King Charles Spaniel
and Golden Retrievers, two each of Cocker Spaniels and
Dogue de Bordeaux, and one each of Greyhound,
Schnauzer, Toy Poodle, Border Terrier, Kerry Blue Terrier,
Rottweiler, Shar Pei, Weimaraner, Boxer, Staffordshire
Terrier, Yorkshire Terrier, and Crossbreed dog. Histopath-
ology in this group was consistent with IBD in 13 dogs,
IBD with IL in four dogs, and IL only present in five dogs.
There was no statistically significant difference in age or
breed distribution between the two PLE dog groups
(p = 0.35 and p = 0.42, respectively). Median Body Condi-
tion Score (BCS)2 was not different between the two
groups (group with good outcome 4.5 (range 1–6), and
group with negative outcome 3.8 (range 1–5), p = 0.5).
The percentage of dogs receiving immunosuppressive
drugs between outcome groups was significantly differ-
ent, with the negative outcome drugs receiving more im-
munosuppressive drugs (p < 0.001). A greater number of
dogs treated with diet alone were in the good outcome
(13/22) group versus PLE dogs in the negative outcome
group (2/21, p < 0.001).
Median serum albumin concentration was 17 g/l
(reference range 28–35), with no difference observed
between the outcome groups (good outcome group: me-
dian 19, range 12–26; negative outcome group: median
16, range 10–27, p = 0.23). Serum albumin concentra-
tion was not correlated with either iCa, 25(OH) D or
CCECAI (r2 = 1.15; r2 = 0.21; and r2 = 0.004,
respectively).
The median 25(OH) D concentration was 23 nmol/L
(range 0–81 nmol/L, [reference range 60–215 nmol]), being
significantly lower in the negative outcome group
(16.5 nmol/L, range 0–66 nmol/L) versus the good out-
come group (37 nmol/L, range 6–81 nmol/L, p = 0.017)
(Figure 1). Hypovitaminosis D was present in 17 dogs
(81%) of the good outcome group and was not statistically
different (p = 0.65) than its occurrence in the 20 dogs
(91%) of the negative outcome group [reference range 60–
215 nmol]). Higher 25(OH) D serum concentration at PLE
diagnosis indicated better prognosis for survival with a haz-
ard ratio of 0.974 (95% CI 0.949, 0.999) for each one nmol/l
increase in 25(OH) D serum concentration (Figure 2).
Serum iCa concentrations were measured at the time of
diagnosis in 41 of the 43 patients. The median serum iCa
concentration in the combined cohorts of PLE dogs was
1.22 mmol/L (range 0.79–1.45 mmol/L, [reference range
1.25–1.45 mmol/L]). In the good outcome group (n = 21),
the median serum iCa concentration was 1.25 mmol/L
(range 0.79–1.35 mmol/L) with 10 dogs having iCa concen-
tration below reference range. In the negative outcome
group (n = 20), the median serum iCa concentration was
1.18 nmol/L (range 0.84–1.45 mmol/L), with 13 dogs having
Allenspach et al. BMC Veterinary Research  (2017) 13:96 Page 3 of 6
iCa concentrations below the reference range. There was a
moderate positive correlation between serum iCa and
25(OH) D concentrations (r = 0.52, p < 0.0005).
The CCECAI scores between the good versus negative
outcome groups were not statistically significant (negative
outcome group: median 8, range 4–19; good outcome
group: median 7, range 4–13; p = 0.6). There was no cor-
relation between CCECAI scores or BCS and 25(OH) D
concentrations (CCECAI: r = 0.043, p = 0.786; BCS:
r = 0.069, p = 0.465). Treatment with immunosuppressive
drugs and low serum 25(OH) D concentration at diagno-
sis were the only factors associated with negative outcome
(univariate logistic regression: p = 0.006 and p = 0.024,
respectively). 25(OH) D serum concentration was the only
significant (p = 0.033) risk factor in the multivariable
logistic regression analysis, with an increase of 25(OH) D
level reducing the odds of having a poor outcome (odds
ratio = 0.96, 95% confidence interval: 0.93–0.997).
Discussion
Decreased iCa serum concentrations have previously
been described with PLE possibly due to malabsorption
of Vitamin D in dogs with severe mucosal disease [10].
This study shows for the first time that low 25(OH) D
serum concentrations and low iCa serum concentrations
are highly prevalent in a cohort of PLE dogs, and that
decreased 25(OH) D serum concentrations are signifi-
cantly associated with negative outcome.
There was no significant correlation between age and
outcome of PLE patients, similar to an earlier report [10].
We also could not confirm any breed associations with
poor outcome; however, this lack of association was likely
influenced by the low number of susceptible breeds (e.g.,
Rotties and Yorkies) found in the study population.
There was a significant correlation between treatment
group (diet versus diet + drugs) and outcome of PLE pa-
tients. The majority of patients in the good outcome group
were managed solely with nutritional therapy, while the
majority of patients in the poor outcome group were
treated with diet and immunosuppressive drug protocols.
Clinical disease severity, as determined by CCECAI and
BCS at the time of diagnosis, was not significantly different
between the two groups suggesting that disease activity was
not a significant variable affecting outcome. The fact that
BCS was not different between the PLE groups also indi-
cates that poor nutritional status alone was not predictive
of outcome. Finally, there was no significant correlation be-
tween CCECAI scores, BCS, and 25(OH) D concentration
at diagnosis with regards to outcome prognosis. It is there-
fore likely that the treatment group was merely a marker
for response to management, and therefore not an inde-
pendent predictor for outcome. Moreover, the BCS system
used in this system has not been independently validated
and it is therefore possible that more sensitive methods to
assess body condition, such as bone density measurement
(DEXA), may have shown different results.
Serum albumin concentration was not identified as a nega-
tive prognostic indicator in this cohort of dogs with PLE. In
previous publications, albumin was found to be correlated
with poor prognosis in dogs with chronic enteropathies in
general [14, 16] as well as in Yorkshire Terriers with PLE [4].
However, other studies investigating canine PLE were unable
to correlate albumin with negative outcome [7, 13]. It is
possible that serum albumin is more important as a prog-
nostic indicator when it is only slightly to moderately below
the reference range [14] and less important once the albumin
concentration is severely low. In addition, we could not find
a correlation between serum albumin concentration and iCa,
Fig. 2 Kaplan-Meier curve and Cox regression using >16 nmol/l,
117–41 nmol/l, and >42 nmol/l as cut-off points for 25(OH) D serum
concentration. Higher (25(OH) D serum concentration at diagnosis
indicated a better survival of PLE dogs with an hazard ratio of 0.974







Fig. 1 Box and Whisker plots representing 25(OH) D serum
concentrations between PLE dogs in the poor outcome versus good
outcome groups. (25(OH) D serum concentration in poor outcome
group: median 16.5 nmol/L, range 0–66 nmol/L; good outcome
group: median 37 nmol/L, range 6–81 nmol/L, p = 0.017)
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serum 25(OH) D concentrations or CCECAI. This indicates
that loss of Vitamin D-binding protein alone is probably not
the sole factor for decreased serum 25(OH) D concentra-
tions in these dogs. Furthermore, it may indicate that serum
25(OH) D concentration is an important metabolite to
measure in these patients, as serum albumin alone may not
be predictive for outcome.
Several studies have described dogs with gastrointestinal
disease and low total and iCa serum concentrations are
often prone to hypocalcemia even after clinical improve-
ment [9, 18, 19]. This could possibly be due to serum vita-
min D levels not being corrected and/or increased fraction
of serum ionized calcium. In humans with vitamin D defi-
ciency, survival is significantly better in patients with nor-
mal vitamin D levels compared to severely ill patients with
vitamin D deficiency [20]. In addition, median serum
concentrations in the group with poor outcome were in the
deficiency range for people as defined by the Institue of
Medicine Consensus Guidelines,3 whereas those dogs in
the group with good outcome had median 25(OH) D
serum concentrations in the insufficient range. There are
no official guidelines available for dogs, but the data pre-
sented here suggest that clinicians should consider measur-
ing 25(OH) D serum concentrations in dogs with PLE and
possibly supplement this vitamin in deficient cases.
A limitation of this study is its retrospective nature and
therefore, the interpretation of clinical data used in this
study. In addition to the fact that the non- standardized
treatment approach could have biased the study, it is also
possible that other confounding variables, such as previous
treatment protocols and dietary intake before diagnosis
were not accounted for. The use of RIAs has historically
been less accurate than the gold standard techniques of
liquid chromatography-mass spectometry (LC-MS). Fur-
thermore, RIAs recognize both 25(OH) D as well as 24,
25(OH) D2 and other polar metabolites, and therefore may
overestimate 25(OH) D levels by approximately 10–20% as
compared to LC-MS. This fact should be taken into ac-
count when interpreting the results of this study. The RIA
used in this study has an intra-assay repeatability (12 repli-
cates), % coefficients of variation for serum pools of 30,
109, and 183 nmol/L of 5.0, 4.6, and 4.2%, respectively. For
interassay repeatability (13 assays), the % coefficients of
variation serum pools of 32 and 115 nmol/L are 15.3 and
10.3%, respectively [16].
Future studies investigating vitamin D status in dogs
should be performed using the gold standard tests as well
as standard quality control schemes for laboratories, such
as the Vitamin D External Quality Assurance Scheme
(DEQAS4).
It is important to note that an association between low
25-hydroxyvitamin D and outcome in this cohort of PLE
dogs was found, however, this does not imply any causal
association between the two parameters.
Conclusions
This is the first study to demonstrate a link between low
vitamin D serum concentration and outcome in canine
PLE patients. Further studies are required to investigate
calcitriol as a potential adjuvant therapeutic agent in
PLE patients as has been shown in other models.
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25(OH) D: 25-hydroxyvitamin D; BCS: Body Condition Score;
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